Literature DB >> 23419490

Prostate cancer: towards appropriate use of androgen deprivation therapy.

Vahakn B Shahinian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23419490     DOI： 10.1038/nrurol.2013.27

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.

Authors:  Maisa Yoshimoto; Jean-Claude Cutz; Paulo A S Nuin; Anthony M Joshua; Jane Bayani; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Cancer Genet Cytogenet       Date:  2006-09

Review 3.  Update on prostate cancer chemoprevention.

Authors:  Jennifer Fisher Lowe; Lawrence A Frazee
Journal:  Pharmacotherapy       Date:  2006-03       Impact factor: 4.705

4.  Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.

Authors:  A R Kuykendal; L H Hendrix; R G Salloum; P A Godley; R C Chen
Journal:  Ann Oncol       Date:  2012-12-30       Impact factor: 32.976

5.  Intermittent androgen suppression for rising PSA level after radiotherapy.

Authors:  Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

6.  Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.

Authors:  Alcides Chaux; Sarah B Peskoe; Nilda Gonzalez-Roibon; Luciana Schultz; Roula Albadine; Jessica Hicks; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Mod Pathol       Date:  2012-06-08       Impact factor: 7.842

7.  Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.

Authors:  Yong-Fang Kuo; James E Montie; Vahakn B Shahinian
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

Review 8.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

9.  Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Authors:  Shidong Jia; Xueliang Gao; Sang Hyun Lee; Sauveur-Michel Maira; Xiaoqiu Wu; Edward C Stack; Sabina Signoretti; Massimo Loda; Jean J Zhao; Thomas M Roberts
Journal:  Cancer Discov       Date:  2012-12-20       Impact factor: 39.397

10.  Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.

Authors:  Whitney Banach-Petrosky; Walter J Jessen; Xuesong Ouyang; Hui Gao; Jayashree Rao; John Quinn; Bruce J Aronow; Cory Abate-Shen
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.